Women with rapidly lethal ovarian cancer are more likely to harbor tumors lacking a normal complement of two enzymes that facilitate the silencing of genes, a new study shows. Meanwhile, patients who survive significantly longer tend to have ample supplies of both compounds, scientists report in the Dec.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.